Posts Tagged ‘biotechnology’

Right Turn: A proliferating list of popular podcasts

Author: Stacey Johnson, 11/25/16

Podcasts have been around since the 1980s and with 250,000 unique podcasts in more than 100 languages, according to Apple, you can probably find one that covers any topic you care to search for. Back in 2014, Lisa Willemse encouraged Signals’ readers to tune in to The Stem Cell Podcast and I mentioned them last…Read more

Right Turn: Bone grafts, made-to-order

Author: Peter Raaymakers, 12/26/14

In a TED video from earlier in the year, Nina Tandon and Sarindr Ick Bhumiratana of EpiBone talked about their incredible technique to use biomaterials and stem cells to generate customized bone material for implant. In Tandon’s words, “If you need a piece of human bone, you can use your own cells to grow your own.” EpiBone’s…Read more

Regenerative Medicine Deal Review: April

Author: Mark Curtis, 05/14/14

. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more. New York-based NeoStem (NBS) entered into a definitive agreement to purchase California…Read more

Cell Therapy Commercialization: Look for Headroom

Author: Mark Curtis, 04/30/14

. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is biotechnology development, and sinking what is likely hundreds of millions of…Read more

Right Turn: Time to stop the bleeding

Author: Roshan Yoganathan, 04/17/14

Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the battlefield. It is used to help stop the bleeding and help sustain the…Read more

Right Turn: Heart in a box – are we there yet?

Author: Roshan Yoganathan, 03/07/14

. I’m not sure many of you are die-hard biomaterial fans like me, but there was a shot heard around the biomaterial world when Canada’s very own Professor Michael Sefton, at the University of Toronto, proposed creating a heart in a box. He made the claim nearly ten years ago. I bring this up now…Read more

Right Turn: Biomaterials for the 21st Century – Repairing spinal cords

Author: Stacey Johnson, 02/21/14

. Dr. Robert Langer’s enthusiasm for the limitless promise of bioengineering is infectious. With his efforts and under his tutelage, one hopes that huge advances will be made in restoring movement to the paralyzed and curing the sick through, for example, more effective drug delivery systems that can manipulate how long and where in the…Read more

Regenerative Medicine Deal Review: January

Author: Mark Curtis, 02/11/14

. Welcome to your Regenerative Medicine Deal Review for the month of January! There was lots of flow in January, including yet another research collaboration from Cellular Dynamics International – this time with the Nestle Institute of Health Sciences to use the company’s iCell® and MyCell® products for research into human nutrition. Aastrom entered into…Read more

Update from the Clinic: January

Author: Mark Curtis, 02/04/14

. Welcome to your Update from the Clinic for the month of January! We start the year off with the German health authority approving Pluristem’s next generation GMP cell manufacturing facility. Neuralstem successfully, and safely, transplants NSI-556 cells directly into the brain of its first patient in a Phase 1/2 study. Meanwhile, OncoMed and StemCells…Read more

Regenerative Medicine Deal Review: December

Author: Mark Curtis, 01/13/14

. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA. Cellular Dynamics International is back in the news this month with another collaboration, this time to…Read more